S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of criti… Read more
S.Biomedics Co. Ltd. (304360) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.015x
Based on the latest financial reports, S.Biomedics Co. Ltd. (304360) has a cash flow conversion efficiency ratio of -0.015x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-158.26 Million) by net assets (₩10.46 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
S.Biomedics Co. Ltd. - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how S.Biomedics Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
S.Biomedics Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of S.Biomedics Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A
SHE:301290
|
N/A |
|
Shanghai W Ibeda High Tech Group Co Ltd
SHG:688071
|
0.015x |
|
Yibin Paper Industry Co Ltd
SHG:600793
|
0.088x |
|
Road Environment Technology Co. Ltd. A
SHG:688156
|
N/A |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
N/A |
|
Ganzhou Yihao New Materials Co. Ltd. A
SHE:301176
|
-0.054x |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
0.068x |
|
InBody Co.Ltd
KQ:041830
|
0.032x |
Annual Cash Flow Conversion Efficiency for S.Biomedics Co. Ltd. (2022–2024)
The table below shows the annual cash flow conversion efficiency of S.Biomedics Co. Ltd. from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩11.86 Billion | ₩-3.50 Billion | -0.295x | +66.74% |
| 2023-12-31 | ₩6.93 Billion | ₩-6.15 Billion | -0.887x | -204.57% |
| 2022-12-31 | ₩-3.78 Billion | ₩-3.21 Billion | 0.848x | -- |